Trial Profile
A Study to Evaluate the Efficacy and Safety of Beclabuvir in Combination with Peginterferon alfa-2a and Ribavirin in Treatment Naive, Non-cirrhotic Patients Infected with Hepatitis C Virus Genotype 1.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Dec 2015
Price :
$35
*
At a glance
- Drugs Beclabuvir (Primary) ; Interferon alpha-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 04 Dec 2015 New trial record